

Christine Longvert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020427/publications.pdf>

Version: 2024-02-01

21
papers

283
citations

1163117

8
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

491
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. <i>Oncolimmunology</i> , 2018, 7, e1442166. | 4.6 | 57 |
| 2 | Incidence and Clinical Impact of Anti-TNF \pm Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolite Survey. <i>Journal of Immunotherapy</i> , 2019, 42, 175-179. | 2.4 | 57 |
| 3 | Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. <i>Annals of Oncology</i> , 2015, 26, 1470-1475. | 1.2 | 46 |
| 4 | Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, . | 2.4 | 22 |
| 5 | Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. <i>Rheumatology</i> , 2021, 60, 5753-5764. | 1.9 | 17 |
| 6 | Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714. | 5.1 | 14 |
| 7 | Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. <i>European Journal of Dermatology</i> , 2019, 29, 636-640. | 0.6 | 12 |
| 8 | Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 948-954. | 6.4 | 11 |
| 9 | Increase in NRAS mutant allele percentage during metastatic melanoma progression. <i>Experimental Dermatology</i> , 2016, 25, 472-474. | 2.9 | 8 |
| 10 | Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9537-9537. | 1.6 | 8 |
| 11 | Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. <i>BMC Cancer</i> , 2015, 15, 732. | 2.6 | 7 |
| 12 | Reply to the letter to the editor "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance" by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 364-365. | 1.2 | 6 |
| 13 | Hyponatremia and MAPK kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331. | 3.3 | 5 |
| 14 | Carpal Tunnel Syndrome: A New Adverse Effect of Immune Checkpoint Inhibitors, 11 Cases. <i>Journal of Immunotherapy</i> , 2021, 44, 122-126. | 2.4 | 5 |
| 15 | On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 91, 174-176. | 2.8 | 2 |
| 16 | Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21008-e21008. | 1.6 | 2 |
| 17 | Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed death receptor-1 monoclonal antibodies. <i>British Journal of Dermatology</i> , 2021, 184, 746-748. | 1.5 | 1 |
| 18 | Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8540-8540. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Treatment of dermatofibrosarcoma protuberans (DFSP) with fixed Mohs micrographic surgery (f-MMS).. Journal of Clinical Oncology, 2015, 33, e20066-e20066. | 1.6 | 1 |
| 20 | Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.. Journal of Clinical Oncology, 2018, 36, e21549-e21549. | 1.6 | 1 |
| 21 | Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. Journal of Clinical Oncology, 2014, 32, 9016-9016. | 1.6 | 0 |